Volpara share price on watch after strong third quarter update

The Volpara Health Technologies Ltd (ASX:VHT) share price will be on watch after the release of a strong third quarter update…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Volpara Health Technologies Ltd (ASX: VHT) share price will be one to watch on Tuesday after the release of its quarterly update.

How did Volpara perform in the third quarter?

This morning the SaaS medical technology company whose AI imaging algorithms assist the early detection of breast cancer revealed further strong cash receipts growth.

According to the release, cash receipts from customers came in at NZ$4.5 million during the third quarter. This was a massive 138% increase compared to the prior corresponding period.

This took its Annual Recurring Revenue (ARR) to NZ$16.8 million at the end of the period. This was ahead of its midrange forecasts.

One key driver of its strong quarter was last year's acquisition of the MRS business in the key United States market. Management notes that more customers are taking advantage of Volpara's enhanced product suite and are adopting a SaaS model.

Supporting its growth was further market share gains. At the end of the quarter, approximately 25.94% women being screened (approx. 10.2 million women) were covered by at least one Volpara product.

Pleasingly, also growing was its average revenue per unit (ARPU). The release advised that the ARPU generated by women under contract across the group within breast cancer operations is currently approximately NZ$1.57 (US$1.02). This is up ~5% from NZ$1.49 (US$0.97) at the end of the second quarter.

As a result of this strong quarter, management is confident it will exceed its midpoint guidance for FY 2020 ARR of NZ$17.1 million (US$11.5 million).

Cash outflows.

Operating cash outflow for the period was NZ$4.5 million. This was largely a result of increased outgoings related to the Radiology Society of North America (RSNA) show in Chicago in early December. Pleasingly, its operating costs continue to run at budget.

Volpara's cash on hand was NZ$35.4 million at the end of the period. This compares to NZ$40.2 million at the end of the second quarter.

Another quarter of strong growth.

Volpara's CEO, Dr Ralph Highnam, was pleased with the third quarter.

He said: "Following a stronger-than-expected Q2, we've now followed up with another quarter of strong growth which has helped us to expect an increase in our ARR forecast for the year. I'm particularly pleased we're starting now to see the combined SaaS orders coming in and the process underway to encourage MRS's legacy installed base to move from their old service & maintenance agreements onto SaaS."

Dr Highnam also notes that the publication of the DENSE trial results in the New England Journal of Medicine were a major highlight during the period. This trial showed a significant drop in interval cancers.

He said: "Trials like DENSE, using Volpara Density, provide the evidence that global screening programs need to change."

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of VOLPARA FPO NZ. The Motley Fool Australia has recommended VOLPARA FPO NZ. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »

Father in the ocean with his daughters, symbolising passive income.
Dividend Investing

I'd spend $8k on these ASX 200 shares today to target a $6,102 annual passive income

I believe these ASX 200 shares will continue rewarding passive income investors for years to come.

Read more »

Three businesspeople leap high with the CBD in the background.
Share Market News

Boom! ASX 200 blasts to new record highs

ASX 200 investors just sent the benchmark index into uncharted territory.

Read more »